Are monotherapy options reasonable for T3 prostate cancer?
Semin Urol Oncol 1997;15(4):207-14

Schellhammer PF; Lynch DF
Department of Urology and the Virginia Prostate Center of Eastern
Virginia Medical School and Sentara Cancer Institute, Norfolk, USA.

In 1997, we believe that either surgery, radiation, or hormonal
monotherapy are unlikely to be adequate therapy alone for clinical
stage T3 prostate cancer and that primary treatment strategies should
use combination therapy. Combination therapies have been investigated
in an effort to lessen the impact of monotherapy failure, and
combination therapy trials have been shown to diminish the incidence
of local failure and increase the time to progression. To gauge the
role that irradiation or surgical monotherapy may play in clinical
stage T3 disease, this article analyzes series that report local and
distant disease control.